Emcure Pharma Receives USFDA EIR for Sanand Facility; Inspection Closed

Emcure Pharmaceuticals Ltd has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations facility located in Sanand, Ahmedabad, Gujarat. The USFDA has classified the inspection status of this facility as Voluntary Action Indicated (VAI), signifying that the inspection is now closed. This update follows a previous intimation regarding the inspection conducted between May 06, 2026, and May 15, 2026. The VAI classification is generally viewed positively by the market as it indicates no major compliance issues requiring significant corrective actions.